Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

Withdrawn before enrolling · Phase 2/Phase 3

Conditions studied: Refractory Epilepsy

In brief

The study will investigate the efficacy of the N-methyl-D-aspartate receptor antagonist ketamine as a first line agent in refractory status epilepticus versus traditional general anesthetic agents used for burst suppression that target the gamma-aminobutyric acid adrenergic receptors.

Key facts

Study ID

NCT03115489

Run by

University of Alabama at Birmingham

People needed

0

Starts

2017-05-04

Expected to finish

2021-05-18

Last updated by the study team

2021-05-21

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients more than 18 years of age with a diagnosis of status epilepticus
• Considered for burst suppression therapy after failing 2 or 3 anti-epileptic medications

You may not qualify if…

• Post anoxic status epilepticus
• Pregnant women, as confirmed by urine, or blood human chorionic gonadotropin, ultrasound or physical exam
• Prisoners
• Age less than 18 years
• Allergy or sensitivity to the drug in question

Where it is running

• UAB Department of Anesthesiology and Perioperative Medicine — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.